TECHNOLOGY FOCUS - INORGANIC CHEMISTRY - Preferred Components: The inorganic base is selected from sodium carbonate, potassium carbonate, sodium hydride, sodium bicarbonate, and/or potassium bicarbonate (preferably sodium bicarbonate).    TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Process: The treatment of 2,3-dimethyl-6-nitro-2H-indazole with Raney nickel is carried out in the presence of hydrogen gas and an organic solvent. The compound (II) is isolated from the reaction mixture. The compound (II) is treated with a suitable solvent selected from halogenated solvents, and/or aliphatic hydrocarbon solvents. The treatment of the compound (II) with 2,4-dichloropyrimidine is carried out in the presence of a base. The treatment of the compound (II) with 2,4-dichloropyrimidine is carried out in the presence of an organic solvent. The step ii) is carried out at less than or equal to 45 degrees C. The compound (II) is not isolated from the reaction mixture. Preferred Components: The organic solvent is selected from methanol, ethanol, n-propanol, iso-propanol, n-butanol, iso-butanol, and/or sec-butanol (preferably methanol). The halogenated solvent is selected from dichloromethane, dichloroethane, chloroform, and carbon tetrachloride; and the aliphatic hydrocarbons is selected from n-pentane, n-hexane, n-heptane, and n-octane. The base is selected from an organic base or an inorganic base. The organic base is selected from N,N-diisopropylethylamine, triethylamine, tri-isopropylamine, N,N-2-trimethyl-2-propanamine, N-methylmorpholine, 4-dimethylaminopyridine, 2,6-di-fert-butyl-4-dimethylaminopyridine, 1,4-diazabicyclo(2.2.2)octane, and/or 1,8-diazabicyclo(5.4.0)undec-7-ene. ACTIVITY - None given.    MECHANISM OF ACTION - Tyrosine kinase inhibitor. No biological data is given.    EXAMPLE - 12.50 g Raney nickel was added to a suspension of 50 g 2,3-dimethyl-6-nitro-2H-indazole in 500 ml methanol. The reaction mixture was stirred in an autoclave under hydrogen pressure of 3.5-4 kg/cm2 at 25-30 degrees C for 5 hours. After work-up, 95 wt./wt.% 2,3-dimethyl-2H-indazol-6-amine was obtained. 112 g Sodium bicarbonate was added to a stirred solution of 2,3-dimethyl-2H-indazol-6-amine in methanol. 99.35 g 2,4-Dichloropyrimidine was added to the reaction mixture followed by stirring of the reaction mixture for 24 hours at 25-30 degrees C. 850 ml De-ionized water was added to the reaction mixture followed by stirring of the reaction mixture at 25-30 degrees C for 1 hour. After work-up, 86.7 wt./wt.% N-(2-chloropyrimidin-4-yl)-2,3-dimethyl-2H-indazol-6-amine was obtained. 238 g Cesium carbonate and 57 g iodomethane were added to a stirred suspension of 100 g N-(2-chloropyrimidin-4-yl)-2,3-dimethyl-2H-indazol-6-amine in 300 ml N,N-dimethylformamide at 25-30 degrees C. The reaction mixture was further stirred at 25-30 degrees C for 6 hours followed by cooling of the reaction mixture to 0-5 degrees C. 300 ml De-ionized water was added drop-wise to the reaction mixture, then the reaction mixture was stirred at 5-10 degrees C for 30 minutes. The solid was collected by filtration, and washed with 200 ml de-ionized water. The wet material so obtained was dried in an air oven at 50 degrees C for 12 hours to obtain 90.4 wt./wt.% pazopanib hydrochloride.